John P. Sharp
2020 - PhaseBio Pharmaceuticals
In 2020, John P. Sharp earned a total compensation of $844.4K as Chief Financial Officer at PhaseBio Pharmaceuticals, a 13% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $120,000 |
|---|---|
| Option Awards | $328,000 |
| Salary | $386,600 |
| Other | $9,819 |
| Total | $844,419 |
Sharp received $386.6K in salary, accounting for 46% of the total pay in 2020.
Sharp also received $120K in non-equity incentive plan, $328K in option awards and $9.8K in other compensation.
Rankings
In 2020, John P. Sharp's compensation ranked 9,283rd out of 13,090 executives tracked by ExecPay. In other words, Sharp earned more than 29.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,283 out of 13,090 | 29th |
Division Manufacturing | 3,963 out of 5,624 | 30th |
Major group Chemicals And Allied Products | 1,608 out of 2,257 | 29th |
Industry group Drugs | 1,407 out of 1,957 | 28th |
Industry Pharmaceutical Preparations | 1,031 out of 1,462 | 30th |
Source: SEC filing on April 22, 2022.
Sharp's colleagues
We found two more compensation records of executives who worked with John P. Sharp at PhaseBio Pharmaceuticals in 2020.